融券方面，麦迪科技12月18日融券偿还0.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 4524.00元；融券余量900.00股，融券余额1.36万元，超过近一年90%分位水平，处于高位。 机构持仓方面，截止2025年9月30日，麦迪科技十大流通股东中，鹏华碳中和主题混合A（016530）退 出十大流通股东之列。 资料显示，苏州麦迪斯顿医疗科技股份有限公司位于江苏省苏州工业园区归家巷222号，成立日期2009 年8月14日，上市日期2016年12月8日，公司主营业务涉及提供临床医疗管理信息系统(CIS)系列应用软 件和临床信息化的整体解决方案。主营业务收入构成为：自制软件40.39%，运维服务31.55%，医疗服 务21.12%，整体解决方案4.60%，外购软硬件1.95%，其他0.40%。 责任编辑：小浪快报 截至9月30日，麦迪科技股东户数3.89万，较上期增加7.17%；人均流通股7864股，较上期减少6.69%。 2025年1月-9月，麦迪科技实现营业收入2.23亿元，同比减少38.13%；归母净利润3426.98万元，同比增 长120.49%。 12月18日，麦迪科技跌0.26%，成交 ...

Core Viewpoint - The company has successfully turned around its financial performance by divesting from its photovoltaic business and focusing on its core medical information technology sector, leading to significant profit growth and improved operational efficiency [1][2]. Financial Performance - In the first half of 2025, the company achieved a net profit attributable to shareholders of 28.33 million yuan, a substantial increase of 137.11% year-on-year, marking a return to profitability [1]. - The company's asset-liability ratio has significantly decreased, and cash flow conditions have improved following the divestment of the photovoltaic business [2]. Business Structure - The core business of medical information technology remains stable, with ongoing innovation and expansion into new areas such as health care robots, which are currently in the scenario validation phase [2]. - The company has developed a comprehensive smart robot health care solution that integrates intelligent interaction, big data analysis, and health management, targeting elderly and rehabilitation patients [2]. Research and Development Investment - The company plans to invest 43.55 million yuan in new projects focused on innovative product development, including low-altitude medical rescue and smart medical service robots [3]. - An additional 130 million yuan is earmarked for upgrading products and services based on large model artificial intelligence technology, aiming to enhance the existing smart medical product system [3]. Strategic Focus - The company emphasizes that medical information technology remains its core value, having established applications in over 2,400 medical institutions across the country, which provides a strong foundation and competitive advantage [3]. - The company is strategically positioned in the auxiliary reproductive business, with its Haikou Mary Hospital being the second private hospital in Hainan to obtain a reproductive license, indicating a stable operation in a scarce market [4]. Synergy and Market Opportunities - The company is exploring synergies between its various business segments, leveraging data and technology to enhance overall competitiveness and core value [4]. - The strategic focus on health care robots and low-altitude emergency rescue aligns with national trends, providing significant market opportunities in elder care and rehabilitation [4].

Core Viewpoint - The company has successfully turned a profit in the first half of 2025, achieving a net profit of 28.33 million yuan despite a significant decline in revenue from its solar business [1]. Financial Performance - The latest stock price of the company is 15.42 yuan, reflecting an increase of 0.52% from the previous trading day [1]. - In the first half of 2025, the company reported total revenue of 135 million yuan and a net profit attributable to shareholders of 28.33 million yuan [1]. - The company completed the disposal of its solar business, resulting in a year-on-year revenue decline of 47.24% [1]. - As of the end of the second quarter, the company had total assets of 1.255 billion yuan and net assets attributable to shareholders of 828 million yuan [1]. Business Operations - The company specializes in clinical medical management information systems and overall solutions for clinical information [1]. - The company has made significant progress in medical information technology innovation, including the localization adaptation of critical care software and the "Xinchuang" transformation [1]. - A strategic partnership has been established with Huawei to enhance its medical services [1]. - The subsidiary, Mary Hospital, completed 568 egg retrieval cycles and 630 transplantation cycles [1]. Market Activity - On August 19, the company experienced a net outflow of 4.54 million yuan in principal funds, with a cumulative net outflow of 72.61 million yuan over the past five days [1].

Company Overview - Madi Technology closed at 15.44 yuan, up 2.93%, with a latest price-to-book ratio of 5.75 and a total market capitalization of 4.729 billion yuan [1] - As of the first quarter of 2025, there is one institutional holder of Madi Technology, holding a total of 49.2201 million shares valued at 0.637 billion yuan [1] Business Operations - Suzhou Madi Technology Co., Ltd. specializes in providing Clinical Information System (CIS) application software and overall solutions for clinical information management [1] - The company's main products include self-developed software, comprehensive solutions, purchased software and hardware, operational and technical services, medical service income, and photovoltaic battery cells [1] Financial Performance - For the first quarter of 2025, Madi Technology reported operating revenue of 63.34 million yuan, a year-on-year decrease of 43.13% [1] - The net profit for the same period was 23.5959 million yuan, showing a year-on-year increase of 138.55% [1] - The sales gross margin stood at 66.10% [1] Industry Comparison - Madi Technology's price-to-earnings (P/E) ratio (TTM) is -17.79, while the industry average is 113.36 [2] - The industry median P/E ratio is 20.17, indicating that Madi Technology's valuation is significantly lower than the industry average [2] - The total market capitalization of Madi Technology is 4.729 billion yuan, compared to the industry average of 11.359 billion yuan [2]